Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Presents Clinical Case Study from First Human Trial of Regenerative Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal Epilepsy
September 21, 2022 12:00 ET | Neurona Therapeutics
Clinical assessments three-months post-treatment report no serious adverse events and reduced seizure frequency to date in first trial participant Data Safety Monitoring Board clears advancement of...
01_PrimaryLogo_Color_BlueX-100.jpg
Invitae’s Real-World Ciitizen Data Utilized in Praxis Precision Medicines’ PRAX-222 IND Filing
September 20, 2022 08:30 ET | Praxis Precision Medicines, Inc.
SAN FRANCISCO and BOSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Invitae (NYSE: NVTA) and Praxis Precision Medicines, Inc. (NASDAQ: PRAX), today announced that real-world clinical insights from...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Provides Updates on Clinical Stage Pediatric Epilepsy Programs
September 07, 2022 07:30 ET | Praxis Precision Medicines, Inc.
BOSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Zeto and Next Gen Neuro Partner for Remote EEG Monitoring
August 29, 2022 09:00 ET | Zeto, Inc.
SANTA CLARA, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Zeto, Inc., a medical technology company, has announced its partnership with Next Gen Neuro, a continuous and routine EEG monitoring company,...
GMILogo_Vertical-Gradient.png
Neurostimulation Devices Market to hit USD 20.1 billion by 2030, says Global Market Insights Inc.
August 25, 2022 05:15 ET | Global Market Insights Inc.
Selbyville, Delaware, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Neurostimulation Devices Market value is set to cross USD 20.1 billion by 2030, according to a new research report by Global Market Insights...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2022 Financial Results
August 08, 2022 16:01 ET | Praxis Precision Medicines, Inc.
PRAX-944 Phase 2b Essential1 Study topline results expected in 4Q22; primary endpoint updated to efficacy PRAX-562 Phase 1 study completed, confirming biomarker change and potential for wide...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Present at 2022 Wedbush PacGrow Healthcare Conference
August 03, 2022 09:00 ET | Praxis Precision Medicines, Inc.
BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
AMR Logo.png
Global Neuromodulation Market to Reach $4.3 Bn Globally, by 2030, at 6.2% CAGR: Says AMR
June 15, 2022 07:47 ET | Allied Market Research
Portland, OR, June 15, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Neuromodulation Market was estimated at $2.48 billion in 2020, and is...
NeuroSigma.png
NeuroSigma Announces That a Team Led by UCLA Researchers Receives NIH Grant to Conduct a Multicenter Trial of eTNS for Pediatric ADHD
June 14, 2022 11:00 ET | NeuroSigma, Inc.
Double-blind randomized controlled trial will enroll up to 225 children at UCLA and Seattle Children’s Hospital NeuroSigma will provide Monarch eTNS Systems and funding for long-term follow-up ...
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Awarded $8 Million by California Institute for Regenerative Medicine (CIRM) to Support Phase 1/2 Clinical Trial of NRTX-1001 for Chronic Focal Epilepsy
May 26, 2022 16:00 ET | Neurona Therapeutics
CIRM grant awarded to accelerate clinical trial of NRTX-1001, a promising regenerative neuronal cell therapy in adults with drug-resistant seizures NRTX-1001 is the first human cell therapy candidate...